Immunovia AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 0.502 million compared to SEK 0.305 million a year ago. Revenue was SEK 0.513 million compared to SEK 0.344 million a year ago. Net loss was SEK 67.32 million compared to SEK 47.13 million a year ago. Basic loss per share from continuing operations was SEK 2.97 compared to SEK 2.08 a year ago. Diluted loss per share from continuing operations was SEK 2.97 compared to SEK 2.08 a year ago.
For the full year, sales was SEK 1.15 million compared to SEK 0.844 million a year ago. Revenue was SEK 1.2 million compared to SEK 0.956 million a year ago. Net loss was SEK 168.09 million compared to SEK 155.97 million a year ago. Basic loss per share from continuing operations was SEK 7.43 compared to SEK 6.89 a year ago. Diluted loss per share from continuing operations was SEK 7.43 compared to SEK 6.89 a year ago.